4.References
[1] Wenjing Wang , Ying Gao, Dongbao Zhao. Analysis of Prognostic
and Death Risk Factors of Antineutrophil Cytoplasmic Antibody-associated
Vasculitis [J]. Modern instruments and medical treatment
[2] HAZEBROEK M R, KEMNA M J, SCHALLA S, et al. Prevalence and
prognostic relevance of cardiac involvement in ANCA-associated
vasculitis: eosinophilic granulomatosis with polyangiitis and
granulomatosis with polyangiitis [J]. International journal of
cardiology, 2015, 199(170-9.
[3] Wang Bin, Liu Ligo, Li Weirong. Discussion on Quality and Safety
Management Architecture of Hospital Clinical Departments [J]. China
Hospital Administration, 2014, 34 (04): 31-3.
[4] HUNTER R W, WELSH N, FARRAH T E, et al. ANCA associated
vasculitis [J]. BMJ (Clinical research ed), 2020, 369(m1070.
[5] FAUCI A S, HAYNES B F, KATZ P, et al. Wegener’s granulomatosis:
prospective clinical and therapeutic experience with 85 patients for 21
years [J]. Annals of internal medicine, 1983, 98(1): 76-85.
[6] DE GROOT K, HARPER L, JAYNE D R, et al. Pulse versus daily oral
cyclophosphamide for induction of remission in antineutrophil
cytoplasmic antibody-associated vasculitis: a randomized trial [J].
Annals of internal medicine, 2009, 150(10): 670-80.
[7] STONE J H, MERKEL P A, SPIERA R, et al. Rituximab versus
cyclophosphamide for ANCA-associated vasculitis [J]. The New England
journal of medicine, 2010, 363(3): 221-32.
[8] GRECO A, MARINELLI C, FUSCONI M, et al. Clinic manifestations in
granulomatosis with polyangiitis [J]. International journal of
immunopathology and pharmacology, 2016, 29(2): 151-9.
[9] HOFFMAN G S, KERR G S, LEAVITT R Y, et al. Wegener
granulomatosis: an analysis of 158 patients [J]. Annals of internal
medicine, 1992, 116(6): 488-98.
[10] GUILLEVIN L, DURAND-GASSELIN B, CEVALLOS R, et al. Microscopic
polyangiitis: clinical and laboratory findings in eighty-five patients
[J]. Arthritis and rheumatism, 1999, 42(3): 421-30.
[11] REINHOLD-KELLER E, BEUGE N, LATZA U, et al. An
interdisciplinary approach to the care of patients with Wegener’s
granulomatosis: long-term outcome in 155 patients [J]. Arthritis and
rheumatism, 2000, 43(5): 1021-32.
[12] MüLLER A, KRAUSE B, KERSTEIN-STäHLE A, et al. Granulomatous
Inflammation in ANCA-Associated Vasculitis [J]. International
journal of molecular sciences, 2021, 22(12):
[13] JAYNE D, RASMUSSEN N, ANDRASSY K, et al. A randomized trial of
maintenance therapy for vasculitis associated with antineutrophil
cytoplasmic autoantibodies [J]. The New England journal of medicine,
2003, 349(1): 36-44.
[14] Etanercept plus standard therapy for Wegener’s granulomatosis
[J]. The New England journal of medicine, 2005, 352(4): 351-61.
[15] SEO P, MIN Y I, HOLBROOK J T, et al. Damage caused by Wegener’s
granulomatosis and its treatment: prospective data from the Wegener’s
Granulomatosis Etanercept Trial (WGET) [J]. Arthritis and
rheumatism, 2005, 52(7): 2168-78.
[16] STONE J H, HOLBROOK J T, MARRIOTT M A, et al. Solid
malignancies among patients in the Wegener’s Granulomatosis Etanercept
Trial [J]. Arthritis and rheumatism, 2006, 54(5): 1608-18.
[17] PAGNOUX C, HOGAN S L, CHIN H, et al. Predictors of treatment
resistance and relapse in antineutrophil cytoplasmic antibody-associated
small-vessel vasculitis: comparison of two independent cohorts [J].
Arthritis and rheumatism, 2008, 58(9): 2908-18.
Fig 1 : Change in temperature after admission
Fig2 2021-11-22ECG:1.Sinus tachycardia 2. abnormal
T-waves3.low QRS voltages
Fig3 :Coronary artery CTA Imaging
Fig4 2021-11-23 ECG:1.Sinus tachycardia 2.low QRS voltages
V1-V3 low voltage
Fig.5 Echocardiography
Fig6: Angiographic results before and after stent implantation
Fig7 2021-11-28ECG
Table 1 laboratory test